An Observational Study on Health Related Quality of Life and Persistent Symptoms in COVID-19 Patients After Hospitalization at Telangana Institute of Medical Sciences and Research, Gachibowli

2021 ◽  
Author(s):  
Chirali Shah ◽  
B. Y. Keerthi ◽  
Jayasri Helen Gali
2018 ◽  
Vol 61 (5) ◽  
pp. 605 ◽  
Author(s):  
Marlon de Freitas Fonseca ◽  
Lilian Carvalho Aragao ◽  
Felipe Ventura Sessa ◽  
Jose Anacleto Dutra de Resende ◽  
Claudio Peixoto Crispi

2007 ◽  
Vol 16 (9) ◽  
pp. 1453-1460 ◽  
Author(s):  
Dirk Heider ◽  
Katharina Kitze ◽  
Margrit Zieger ◽  
Steffi G. Riedel-Heller ◽  
Matthias C. Angermeyer

2021 ◽  
pp. 125-140
Author(s):  
Jacky Reid ◽  
Andrea Nolan ◽  
Marian Scott

Abstract Animal welfare research is gradually moving towards inclusion of positive welfare, with the consideration of how animals can be provided a good life or a life worth living. The concept of quality of life, which originates from human medical sciences, definitely contributes to this. In this chapter the developers of the health-related quality of life tool for dogs share their expertise.


Author(s):  
M Petitclerc ◽  
M Cloutier ◽  
M Bhogal ◽  
G Davidovic

Background: The clinical benefit of onabotulinumtoxinA in cervical dystonia (CD) is proven, but its impact on health-related quality of life (HRQoL) is largely unknown. Methods: Multicentre, prospective, observational study (NCT01655862) of CD patients treated with onabotulinumtoxinA at physician discretion (maximum 9 treatments). Patient-reported HRQoL outcomes and work productivity were collected at baseline, 4- or 8-weeks post-treatment, and final visit (prior to 9th treatment). OnabotulinumtoxinA utilization was assessed. Results: 61 patients received ≥1 treatment; 74.1% completed all treatments. Average total dose/treatment was 186.9U. The splenius capitis was most frequently treated (100% patients). Average pain numeric rating scale score was significantly improved at final visit (2.1) versus baseline (4.6; p<0.001) as were CD impact profile questionnaire-58 scores across all subscales (head/neck symptoms, pain/discomfort, sleep, upper limb activities, walking, annoyance, mood, psychosocial functioning; all p<0.001). Fewer patients (16.0%) reported loss of work productivity at final visit versus baseline (48.4%). 121 AEs were reported by 67.2% patients. 62 AEs in 44.3% patients were treatment-related, the most common being neck pain (18%). One serious AE (not treatment-related) was reported by 1 patient. No new safety signals were identified. Conclusions: Long-term use of onabotulinumtoxinA is a safe, effective treatment for CD, improving HRQoL and work productivity.


Sign in / Sign up

Export Citation Format

Share Document